Clinical-stage CNS-focused biotech company developing novel therapeutics for schizophrenia, including TerXT, our proprietary prodrugs of xanomeline/trospium, designed to overcome the limitations of Cobenfy via elimination of GI side effects and food effect, and improved dosing via a once-daily oral form as well as a multi-month LAI.